StockNews.AI

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

StockNews.AI • 4 hours

KymriahYescartaPFEAVEO
High Materiality8/10

Information

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic...

Original source

AI Summary

Bria-OTS shows 11-month complete resolution in metastatic breast cancer patient. No treatment-limiting toxicities reported for Bria-OTS therapy. Enrolled patient, aged 78, had multiple previous treatment failures. Phase 2a study of Bria-OTS with immune checkpoint inhibitors underway. Study impacts confidence in Bria-OTS as a therapeutic option.

Sentiment Rationale

The sustained complete response and lack of toxicities can enhance investor confidence, similar to past oncology breakthroughs like Kymriah and Yescarta, which saw price bumps. Clinical updates on successful treatments can positively influence the stock price due to increased interest from investors.

Trading Thesis

Positive clinical results often lead to immediate market reactions, as seen when key trials report success. Investors might react quickly, thereby potentially affecting stock price in the near term.

Market-Moving

  • Bria-OTS shows 11-month complete resolution in metastatic breast cancer patient.
  • No treatment-limiting toxicities reported for Bria-OTS therapy.
  • Enrolled patient, aged 78, had multiple previous treatment failures.

Key Facts

  • Bria-OTS shows 11-month complete resolution in metastatic breast cancer patient.
  • No treatment-limiting toxicities reported for Bria-OTS therapy.
  • Enrolled patient, aged 78, had multiple previous treatment failures.
  • Phase 2a study of Bria-OTS with immune checkpoint inhibitors underway.
  • Study impacts confidence in Bria-OTS as a therapeutic option.

Companies Mentioned

  • Kymriah (Kymriah)
  • Yescarta (Yescarta)
  • PFE (PFE)
  • AVEO (AVEO)

Research Analysis

The announcement showcases significant clinical progress with Bria-OTS, demonstrating potential in a difficult cancer market. Developments of this nature often lead to increased visibility and interest in the company’s stock.

BriaCell Reports 11-Month Complete Resolution of Lung Metastasis in Metastatic Breast Cancer Patient

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT), a clinical-stage biotechnology firm, has reported a significant milestone in its Bria-OTS program. The personalized immunotherapy has achieved the sustained complete resolution of a lung metastasis in a patient suffering from metastatic breast cancer (MBC). This breakthrough provides hope for patients with limited treatment options.

Details of the Clinical Study

The patient, a 78-year-old woman diagnosed with advanced metastatic breast cancer and multiple prior treatment failures, was enrolled in the Bria-OTS Phase 1/2a clinical study. After receiving four doses of Bria-OTS monotherapy, she achieved a complete (100%) resolution of a lung metastasis. This complete response was confirmed over time:

  • Initial observation at 2 months
  • Confirmed at 4 months
  • Verified at 6 months
  • Persisted through to 11 months

The patient has undergone 17 cycles of Bria-OTS and completed 12 months in the study, now continuing in survival follow-up.

Study Advancement and Future Plans

The Phase 1 portion focusing on dose escalation is now complete, and the study progresses into Phase 2a. This phase will explore the effects of combining Bria-OTS with an immune checkpoint inhibitor. Dr. Neal S. Chawla, Director at the Sarcoma Oncology Center and Principal Investigator of the Bria-OTS study, remarked on the significance of the observed clinical response: “The sustained clinical response in this late-stage MBC patient, who previously progressed through multiple treatments, is remarkable.”

Dr. William V. Williams, BriaCell’s President and CEO, added, “These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform.” The company remains dedicated to advancing their therapeutic approach aimed at improving outcomes for patients facing metastatic breast cancer.

About Bria-OTS

Bria-OTS is a next-generation, off-the-shelf personalized immunotherapy derived from BriaCell’s lead candidate, Bria-IMT. It is currently undergoing evaluation in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673) involving patients with metastatic recurrent breast cancer. The investigational trial includes both monotherapy dose escalation and combination cohorts, with the company recently entering a dose expansion phase.

BriaCell Therapeutics Corp. Overview

BriaCell is a dedicated clinical-stage biotechnology firm aiming to revolutionize cancer care through innovative immunotherapies. More information about their initiatives and research can be found on their website at briacell.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including anticipated studies and potential outcomes related to BriaCell’s ongoing research. Please be aware that these statements are subject to risks and uncertainties. Detailed descriptions of these risks can be found in the company’s filings with both Canadian and U.S. regulatory authorities, available on SEDAR+ and EDGAR websites.

Contact Information

Company Contact:
William V. Williams, MDPresident & CEO
1-888-485-6340
info@briacell.com

Investor Relations Contact:
investors@briacell.com

Related News